Breast Cancer Clinical Trials in New York

Showing 341-360 of 718 trials

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

NCT05141708

This non-interventional retrospective study will describe real-world treatment patterns and clinical outcomes among adults with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib as a first or later line of therapy. Patients will be identified from the Flatiron Electronic Health Record database.

Metastatic Breast CancerBreast Neoplasms

Pfizer33 participantsStarted Dec 2021

New York, New York, United States

TERMINATEDPhase 2< 1 mile

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

NCT04461600

The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.

Triple Negative Breast Cancer

Ayala Pharmaceuticals, Inc,18 participantsStarted Aug 2020

Gilbert, Arizona, United States • Phoenix, Arizona, United States • San Francisco, California, United States +26 more locations

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

Breast Cancer Trials in Other Cities

Vaccination With Flt3L, Radiation, and Poly-ICLC

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions

Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

A Study of PRT2527 in Participants With Advanced Solid Tumors

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Other Conditions in New York